A new peer-reviewed study published in the American Journal of Preventive Cardiology finds that tirzepatide — the active ingredient in Mounjaro and Zepbound — can move patients down a full BMI category. That kind of shift matters clinically, because BMI thresholds influence treatment eligibility, surgical risk, and long-term cardiovascular outcomes.
What the Study Found
The research, titled Crossing the line: BMI category changes with tirzepatide, examined whether patients using tirzepatide moved across established BMI boundaries — for example, from obesity (BMI 30+) into the overweight range, or from overweight into a normal weight range. Crossing these thresholds is considered a more clinically meaningful benchmark than raw pounds lost, because official BMI categories are used by clinicians to guide diagnosis, insurance coverage decisions, and cardiovascular risk assessments. The study's publication in a preventive cardiology journal underscores the heart-health implications of this level of weight reduction.
Why a Full BMI Category Matters for Patients
For people taking Zepbound or Mounjaro, this finding reframes how to think about success on the medication. Losing enough weight to cross a BMI threshold can unlock real-world benefits:
- Reduced cardiovascular risk: Moving out of the obese BMI range is associated with lower rates of heart disease and stroke.
- Surgical eligibility changes: Some procedures have BMI cutoffs that determine who qualifies.
- Insurance and coverage criteria: Certain treatments and medications are tied to BMI thresholds.
- Psychological motivation: Crossing a clinical boundary can be a more tangible goal than a target weight number.
Tirzepatide works by activating both GLP-1 and GIP receptors, a dual mechanism that has shown greater average weight loss in trials compared to GLP-1-only medications like semaglutide (Ozempic/Wegovy).
The key takeaway: tirzepatide doesn't just reduce weight — according to this peer-reviewed research, it can move patients across a full BMI classification boundary, a shift with direct implications for cardiovascular risk and clinical decision-making.
What This Means If You're on Mounjaro or Zepbound
If you're currently taking tirzepatide, this study adds to the evidence that the medication can produce weight loss substantial enough to change your clinical classification — not just your appearance or how your clothes fit. Talk with your prescriber about what BMI category you currently fall into and whether crossing a threshold is a realistic treatment goal based on your starting point and dose. It's also worth noting that individual results vary, and the study's specific patient population, dosages studied, and time frames were not detailed in the available source material.
What to Watch Next
As research into tirzepatide's long-term effects continues to grow, look for follow-up studies examining whether patients who cross BMI thresholds on the medication maintain that lower category over time — and what happens if the drug is discontinued. The cardiovascular outcomes data tied to BMI category changes will also be an important area to watch, given this study's publication in a preventive cardiology journal.
Frequently Asked Questions
This study adds meaningful context to what tirzepatide can accomplish, but your individual treatment plan should always be guided by your prescriber. If you're taking Mounjaro or Zepbound — or considering either — talk with your doctor or nurse practitioner about your BMI goals and what this level of weight reduction could mean for your specific health profile.
- Peer-reviewed journal article, 'Crossing the line: BMI category changes with tirzepatide,' American Journal of Preventive Cardiology, date not specified in source material.